Premium
High‐dose Bendamustine‐ EAM followed by autologous stem cell rescue results in long‐term remission rates in lymphoma patients, without renal toxicity
Author(s) -
Noesslinger Thomas,
Panny Michael,
Simanek Ralph,
Moestl Michaela,
Boehm Alexandra,
Menschel Elisabeth,
Koller Elisabeth,
Keil Felix
Publication year - 2018
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13102
Subject(s) - medicine , bendamustine , carmustine , etoposide , melphalan , regimen , transplantation , autologous stem cell transplantation , lymphoma , surgery , gastroenterology , cytarabine , chemotherapy , rituximab
Background Autologous stem cell transplantation ( ASCT ) following BEAM ( BCNU , etoposide, cytarabine, melphalan) conditioning is standard of care in relapsed low‐ and high‐grade B‐cell lymphoma ( DLBCL ) and other lymphoproliferative disorders, but BCNU is associated with interstitial pneumonia and an increased mortality. A less toxic regimen might improve the outcome of patients with lymphoma after transplantation. Objectives We investigated the role of bendamustine replacing BCNU in the BEAM regimen in patients with lymphoma undergoing ASCT . Patients/Methods The conditioning regimen Benda EAM consisted of bendamustine, cytarabine, etoposide, and melphalan and was used in patients with Hodgkin′s disease ( HD ) and Non‐Hodgkin lymphoma ( NHL ). Results Forty‐one patients with HD (n = 9) or NHL (n = 32) were consecutively treated with Benda‐ BEAM replacing BCNU . No pulmonary or renal toxicities occurred, and no patient died related to transplant. After a median follow‐up of 55 months, CR rate was 56%, 18 patients (44%) showed progression after a median time of 7 months after transplantation (range: 2‐29 months), and 11 patients (24%) have died, all due to lymphoma progression. The 1‐, 2‐, and 4‐year PFS are 73.2%, 58.6%, and 55.6% and the 1‐, 2‐, and 4‐year OS 85.4%, 78.0%, and 72.6%, respectively. Conclusion Benda EAM seems to be feasible with a promising response rate and acceptable toxicity.